This trial is active, not recruiting.

Condition hepatitis c
Treatments hep-net intervention, usual care
Sponsor University of Wisconsin, Madison
Collaborator AIDS Resource Center of Wisconsin
Start date August 2014
End date March 2016
Trial size 225 participants
Trial identifier NCT02474043, 2013-1360


The goal of this study is to evaluate the effectiveness of a brief, computerized behavioral intervention for promoting screening for hepatitis C and reducing risky behavior for people who inject drugs (PWID).

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking open label
Primary purpose screening
(Active Comparator)
Standard health education and prevention counseling by trained staff
usual care
Clients receive health education and risk reduction counseling from a trained prevention specialist.
Computerized tailored behavioral intervention
hep-net intervention
The Hep-Net Intervention is a web-based questionnaire and tailored feedback system designed to increase readiness to change with respect to several behaviors. The behaviors include (1) reducing or quitting drug use; (2) using sterile equipment every time one injects drugs; (3) undergoing screening for hepatitis C; (4) receiving training to use naloxone to prevent death due to opioid overdose.
usual care
Clients receive health education and risk reduction counseling from a trained prevention specialist.

Primary Outcomes

Screening for hepatitis C infection
time frame: 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Age 18 or over - English-speaking - Reports injection of illicit drugs in the past month Exclusion Criteria: - Unable to provide informed consent due to cognitive impairment - Unwilling to provide personal locator information and consent to be contacted for follow-up after 3 months. - Currently known to be pregnant

Additional Information

Official title A Community-based, Behavioral Intervention to Improve Screening for Hepatitis C Among High-risk Young Adults in Wisconsin
Principal investigator Ryan Westergaard, MD, PhD
Description People who inject drugs (PWID) are at high risk for hepatitis C virus (HCV) infection if they share contaminated injection equipment with others. Many are infected but are unaware of it, making it likely they will transmit the virus to others if they share contaminated injecting equipment. Problems related to hepatitis C can be avoided if people know their status by getting tested and referred to treatment. In this study, we will recruit eligible PWID in several cities in Wisconsin using a social networks strategy, in which clients who receive services at a syringe exchange program are asked to refer peers who also inject drugs to participate in the study. All participants will undergo a baseline computerized risk assessment that elicits information about hepatitis C status, previous testing, transmission risk behaviors, and overdose risk. Participants will then be randomly-assigned to receive either standard risk reduction counseling from a prevention specialist, or computerized tailored risk reduction messages that are specific to their reported risk behaviors, attitudes and beliefs. A follow-up assessment will be completed after 3 months to evaluate changes in behavioral risk and intention to undergo HCV screening. A database will be searched to determine which participants returned for HCV screening within 12 months of enrollment, and of those, which ones tested positive for HCV.
Trial information was received from ClinicalTrials.gov and was last updated in June 2015.
Information provided to ClinicalTrials.gov by University of Wisconsin, Madison.